Freenome built syndicate strategically for $160M series B

Freenome diversified its investor base for strategic reasons as it assembled a broad syndicate to commit $160 million in series B funding to test the company's machine-learning cancer diagnostics approach in a pivotal study to screen for colorectal cancer.